AstraZeneca’s respiratory and immunology portfolio is driving significant growth, with R&I assets forecasted to account for ...

A viral outbreak in China is raising concerns reminiscent of 2019, but this time the focus is on human metapneumovirus (HMPV) ...

Medicare has chosen 15 prescription medications for price negotiations this year, building off a first round of negotiations ...

We came across a bullish thesis on Bristol-Myers Squibb Company (BMY) on Disruptive analytics’ Substack by Magnus Ofstad. In ...

UK pharma major AstraZeneca’s Fasenra (benralizumab), with its highly anticipated Phase III data to be showcased at the 2025 ...

“Emphysema makes it hard to breathe air out of your lungs as it affects the tiny air sacs at the end of the airways where ...

The upcoming release of Phase III Fasenra data in COPD in 2025 is expected to solidify AstraZeneca’s position in the market.

MRI of inhaled perfluoropropane can assess regional lung ventilation and monitor improvements in response to medication ...

“Emphysema is part of a group of lung conditions which comes under the umbrella term chronic obstructive pulmonary disease ...

Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss treatment Wegovy are among the 15 drugs targeted for ...

A psychoeducational intervention for extrapulmonary manifestations of severe asthma was found feasible and rated as ...